Verve Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $6,865 | $6,692 | $5,695 | $5,144 |
Gross Profit | 5,111 | 5,025 | 4,063 | 3,627 |
EBITDA | -55,156 | -57,172 | -55,212 | -52,431 |
EBIT | -56,910 | -58,839 | -56,844 | -53,948 |
Net Income | -50,133 | -49,805 | -48,736 | -48,352 |
Net Change In Cash | 6,865 | 6,692 | 5,695 | 5,144 |
Free Cash Flow | -40,543 | -35,138 | -43,515 | -42,865 |
Cash | 158,709 | 141,490 | 144,200 | 206,180 |
Basic Shares | 84,632 | 84,226 | 83,132 | 69,671 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $11,758 | $1,941 | $0 | $0 |
Gross Profit | 6,303 | -4,770 | -3,377 | -1,328 |
EBITDA | -217,669 | -162,883 | -85,532 | -39,299 |
EBIT | -223,124 | -169,594 | -87,067 | -40,627 |
Net Income | -200,068 | -157,387 | -118,637 | -45,542 |
Net Change In Cash | 11,758 | 1,941 | 0 | 0 |
Cost of Revenue | 50,669 | 60,111 | ||
Free Cash Flow | -158,832 | -135,564 | -82,239 | -38,689 |
Cash | 206,180 | 115,412 | 64,330 | 8,993 |
Basic Shares | 64,175 | 54,023 | 48,511 | 48,215 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.59 |
2024-06-30 | -$0.59 |
2024-03-31 | -$0.59 |
2023-12-31 | -$0.69 |
